Evidence map›Paper›PMID 29905531›Full record

ArticleAging2018

Is MDMX the better target?

Ning Kon, Wei Gu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Focused Library Generator: case of Mdmx inhibitors.Journal of computer-aided molecular design · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ning KonInstitute for Cancer Genetics, College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA.
Wei GuInstitute for Cancer Genetics, College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA.

Funding

Regulation of p53 acetylation and deacetylation in tumorigenesis.R01CA085533 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GU, WEI · 2000 to 2021
$5.2M
Regulation of SLC7A11 by p53 in cancer metabolismR01CA190477 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GU, WEI · 2016 to 2020
$1.8M
HAUSP inhibitors in p53-wild type and p53-mutant tumorsR01CA193890 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GU, WEI · 2015 to 2019
$1.8M
Mechanisms of targeting oncoprotein SET in tumor suppressionR01CA216884 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GU, WEI · 2017 to 2021
$1.8M
p53 acetylation in ferroptosis and tumor suppressionR01CA224272 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GU, WEI · 2018 to 2021
$1.5M
NCI NIH HHS R01 CA085533NCI NIH HHS R01 CA190477NCI NIH HHS R01 CA193890NCI NIH HHS R01 CA216884NCI NIH HHS R01 CA224272
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AcetylationAnimalsCarcinogenesisGene Expression RegulationGenes, Tumor SuppressorMiceMice, KnockoutMutationNuclear ProteinsProto-Oncogene ProteinsProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53FAM107A protein, humanMdm2 protein, mouseMdm4 protein, mouseNuclear ProteinsProto-Oncogene ProteinsProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53mdm2 KOmdmx KOp53 3KR mutant

Identifiers

PMID29905531
PMCPMC6046243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.